Sarepta Therapeutics (SRPT) Cash from Investing Activities (2010 - 2026)

Sarepta Therapeutics' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$134.4 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 53.85% year-over-year to -$134.4 million; the TTM figure through Mar 2026 stood at $226.4 million (down 7.8% YoY), while the FY2025 annual figure was $69.6 million, down 90.78% from the prior year.
• Cash from Investing Activities was -$134.4 million for Q1 2026 at Sarepta Therapeutics, down from $96.2 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $764.1 million in Q4 2024 to a low of -$785.8 million in Q1 2022.
• Historically, Cash from Investing Activities has averaged -$30.7 million across 5 years, with a median of $9.8 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities sank 1201.37% in 2023, then soared 1651.49% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at $9.8 million in 2022, then slumped by 756.98% to -$64.4 million in 2023, then soared by 1287.29% to $764.1 million in 2024, then tumbled by 87.41% to $96.2 million in 2025, then plunged by 239.69% to -$134.4 million in 2026.
• The last three Cash from Investing Activities figures came in at -$134.4 million (Q1 2026), $96.2 million (Q4 2025), and $232.4 million (Q3 2025), per Business Quant data.